On conclusion of the inspection, the company received one observation in the Form-483.

The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company’s consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.

The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.